The American Journal of Medicine
Volume 116, Issue 3 , Pages 158-164, 1 February 2004

Effect of folic acid fortification of food on homocysteine-related mortality

  • Jeffrey L Anderson, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Jeffrey L. Anderson, MD, Cardiovascular Department, LDS Hospital, 8th Avenue and C Street, Salt Lake City, Utah 84143, USA
    • Cardiovascular Department, LDS Hospital, and University of Utah, Salt Lake City, Utah, USA
  • ,
  • Kurt R Jensen, MS

      Affiliations

    • Cardiovascular Department, LDS Hospital, and University of Utah, Salt Lake City, Utah, USA
  • ,
  • John F Carlquist, PhD

      Affiliations

    • Cardiovascular Department, LDS Hospital, and University of Utah, Salt Lake City, Utah, USA
  • ,
  • Tami L Bair

      Affiliations

    • Cardiovascular Department, LDS Hospital, and University of Utah, Salt Lake City, Utah, USA
  • ,
  • Benjamin D Horne, MStat, MPH

      Affiliations

    • Cardiovascular Department, LDS Hospital, and University of Utah, Salt Lake City, Utah, USA
  • ,
  • Joseph B Muhlestein, MD

      Affiliations

    • Cardiovascular Department, LDS Hospital, and University of Utah, Salt Lake City, Utah, USA

Abstract 

Background

In 1998, the Food and Drug Administration mandated the fortification of food products with folic acid. The effect of this rule on mortality associated with homocysteine levels in patients with coronary artery disease is unknown.

Methods

We studied 2481 consecutive patients with coronary artery disease who underwent coronary angiography between 1994 and 1999, and who had baseline homocysteine measurements and at least 2 years of follow-up. Patients were divided into prefortification (1994 to 1997, n = 1595) and postfortification (1998 to 1999, n = 886) groups, as well as classified based on baseline homocysteine levels (normal to low, intermediate, and high). Homocysteine levels were measured by fluorescence polarization immunoassay. Mortality was determined by telephone survey or from a national Social Security database or hospital records.

Results

After implementation of the fortification rule, median homocysteine levels declined from 13.8 to 12.3 μmol/L (P <0.001), and the proportion of patients with high homocysteine levels (>15 μmol/L) decreased from 41% (n = 650) to 28% (n = 249) (P <0.001). Overall, homocysteine was a modest risk factor for mortality (adjusted relative risk [RR] = 1.03 per μmol/L; 95% confidence interval [CI]: 1.01 to 1.05; P = 0.006). There was no significant interaction between fortification status and homocysteine category with mortality (P for interaction = 0.85). Two-year mortality was reduced minimally (7.8% [n = 124] to 7.2% [n = 64]; RR = 0.93; 95% CI: 0.68 to 1.27; P = 0.63; adjusted RR = 0.97; 95% CI: 0.68 to 1.40), but was consistent with the expectation of a modest reduction in homocysteine levels.

Conclusion

Homocysteine is an independent, graded risk factor for mortality. Homocysteine levels decreased modestly after the fortification of food with folic acid, but the effects on mortality were minor and likely attributable to other factors, indicating the need for more aggressive measures to reduce homocysteine-associated cardiovascular risk.

Keywords:  coronary artery disease, folic acid, food fortification, homocysteine, prevention

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was supported by a grant from the Deseret Foundation, Salt Lake City, Utah, and an in-kind grant from Abbott Diagnostics, Abbott Park, Illinois.

PII: S0002-9343(03)00690-9

doi:10.1016/j.amjmed.2003.10.024

The American Journal of Medicine
Volume 116, Issue 3 , Pages 158-164, 1 February 2004